FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2758660731> ?p ?o ?g. }

• W2758660731 endingPage "S171" @default.
• W2758660731 startingPage "S170" @default.
• W2758660731 abstract "Discordances between the Estrogen receptor [ER], Progesterone receptor [PR] and Human Epidermal growth factor receptor 2 [HER2] expression between the primary tumor and the brain metastasis were investigated in breast cancer (BC) patients with brain metastases (BM). Retrospective data was collected by 11 institutions from 8 countries in a predefined-standardized format. Receptor status (positive or negative) was determined according to institutional guidelines pathology (immunohistochemically and/or fluorescence in situ hybridization). The study was subject to each institution’s ethical research committee. A total of 167 BC patients with BM were included. Patients’ demographics and disease related information are listed in Table 1. Out of 119 patients (71%) that had full receptor information of both primary tumor and BM (ER, PR, and HER2), 25 patients (21%) had a change in receptor status: 7 of 26 (27%) ER/PR positive/HER2 negative primaries (3 gained HER2; 4 lost expression of ER/PR); 10 of 31 (32%) ER/PR positive/HER2 positive primaries (4 lost ER/PR only; 3 lost HER2 only; 3 lost ER/PR and HER2); one of 33 (3%) ER/PR negative receptor/HER2 positive primaries (gained ER) and 7 of 39 (18%) triple negative primaries (5 gained ER/PR and 2 gained HER2). The majority of breast cancer patients with brain-metastases in this series had primary HER2-enriched tumors, followed by a triple negative profile. One out of 5 patients with BC brain metastases had a marker discrepancy between the primary tumor and the subsequent brain metastasis. This may have implications for choice of systemic therapy as it contributes to non-responsiveness to systemic therapies in the CNS. In these cases, obtaining CNS tissue and receptor status may guide deciding on further therapy.Abstract 1003; Table 1Patients’ demographics and disease related informationTotal number of patients[167]Median age at diagnosis (range)[162]49.8(23-81)Stage at diagnosis IIIIIIIV[154]26604721Histology of primary breast cancer IDCILC Other[163]15823Primary molecular subtype HR+/HER-HR+/HER2+HR-/HER2+TN[149]*28 (19%)34 (23%)34 (23%)53 (35%)Median age at diagnosis of BM (range)[151]54(28-91)Median time (years) from diagnosis of primary to BM (range)[149]3 (0-47)BM molecular subtype HR+/HER-HR+/HER2+HR-/HER2+TN[129]*26 (20%)31(24%)33 (26%)39 (30%)The number of patients with available data is written in square brackets for each parameter. IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; HR: hormone receptor (estrogen and/or progesterone); HER2: human epidermal growth factor receptor 2; TN: triple negative; BM: brain metastases; ∗: number of patients with data on all 3 receptors available. Open table in a new tab" @default.
• W2758660731 created "2017-10-06" @default.
• W2758660731 creator A5001236278 @default.
• W2758660731 creator A5006119564 @default.
• W2758660731 creator A5006422634 @default.
• W2758660731 creator A5013720814 @default.
• W2758660731 creator A5014067402 @default.
• W2758660731 creator A5015491251 @default.
• W2758660731 creator A5031825546 @default.
• W2758660731 creator A5038202894 @default.
• W2758660731 creator A5047950011 @default.
• W2758660731 creator A5050746219 @default.
• W2758660731 creator A5055627202 @default.
• W2758660731 creator A5058373918 @default.
• W2758660731 creator A5059236719 @default.
• W2758660731 creator A5061960454 @default.
• W2758660731 creator A5068220065 @default.
• W2758660731 creator A5078658404 @default.
• W2758660731 creator A5079718032 @default.
• W2758660731 creator A5085608144 @default.
• W2758660731 creator A5090280001 @default.
• W2758660731 creator A5090633800 @default.
• W2758660731 date "2017-10-01" @default.
• W2758660731 modified "2023-10-01" @default.
• W2758660731 title "Discrepancies Between Biological Markers of Primary Breast Cancer and Their Brain Metastases: An International Multicenter Study" @default.
• W2758660731 doi "https://doi.org/10.1016/j.ijrobp.2017.06.431" @default.
• W2758660731 hasPublicationYear "2017" @default.
• W2758660731 type Work @default.
• W2758660731 sameAs 2758660731 @default.
• W2758660731 citedByCount "0" @default.
• W2758660731 crossrefType "journal-article" @default.
• W2758660731 hasAuthorship W2758660731A5001236278 @default.
• W2758660731 hasAuthorship W2758660731A5006119564 @default.
• W2758660731 hasAuthorship W2758660731A5006422634 @default.
• W2758660731 hasAuthorship W2758660731A5013720814 @default.
• W2758660731 hasAuthorship W2758660731A5014067402 @default.
• W2758660731 hasAuthorship W2758660731A5015491251 @default.
• W2758660731 hasAuthorship W2758660731A5031825546 @default.
• W2758660731 hasAuthorship W2758660731A5038202894 @default.
• W2758660731 hasAuthorship W2758660731A5047950011 @default.
• W2758660731 hasAuthorship W2758660731A5050746219 @default.
• W2758660731 hasAuthorship W2758660731A5055627202 @default.
• W2758660731 hasAuthorship W2758660731A5058373918 @default.
• W2758660731 hasAuthorship W2758660731A5059236719 @default.
• W2758660731 hasAuthorship W2758660731A5061960454 @default.
• W2758660731 hasAuthorship W2758660731A5068220065 @default.
• W2758660731 hasAuthorship W2758660731A5078658404 @default.
• W2758660731 hasAuthorship W2758660731A5079718032 @default.
• W2758660731 hasAuthorship W2758660731A5085608144 @default.
• W2758660731 hasAuthorship W2758660731A5090280001 @default.
• W2758660731 hasAuthorship W2758660731A5090633800 @default.
• W2758660731 hasConcept C104317684 @default.
• W2758660731 hasConcept C121608353 @default.
• W2758660731 hasConcept C126322002 @default.
• W2758660731 hasConcept C142724271 @default.
• W2758660731 hasConcept C143998085 @default.
• W2758660731 hasConcept C185592680 @default.
• W2758660731 hasConcept C2777542201 @default.
• W2758660731 hasConcept C2778164965 @default.
• W2758660731 hasConcept C2779013556 @default.
• W2758660731 hasConcept C2780110267 @default.
• W2758660731 hasConcept C2780283643 @default.
• W2758660731 hasConcept C29456083 @default.
• W2758660731 hasConcept C30481170 @default.
• W2758660731 hasConcept C530470458 @default.
• W2758660731 hasConcept C55493867 @default.
• W2758660731 hasConcept C71924100 @default.
• W2758660731 hasConcept C84606932 @default.
• W2758660731 hasConcept C98717036 @default.
• W2758660731 hasConceptScore W2758660731C104317684 @default.
• W2758660731 hasConceptScore W2758660731C121608353 @default.
• W2758660731 hasConceptScore W2758660731C126322002 @default.
• W2758660731 hasConceptScore W2758660731C142724271 @default.
• W2758660731 hasConceptScore W2758660731C143998085 @default.
• W2758660731 hasConceptScore W2758660731C185592680 @default.
• W2758660731 hasConceptScore W2758660731C2777542201 @default.
• W2758660731 hasConceptScore W2758660731C2778164965 @default.
• W2758660731 hasConceptScore W2758660731C2779013556 @default.
• W2758660731 hasConceptScore W2758660731C2780110267 @default.
• W2758660731 hasConceptScore W2758660731C2780283643 @default.
• W2758660731 hasConceptScore W2758660731C29456083 @default.
• W2758660731 hasConceptScore W2758660731C30481170 @default.
• W2758660731 hasConceptScore W2758660731C530470458 @default.
• W2758660731 hasConceptScore W2758660731C55493867 @default.
• W2758660731 hasConceptScore W2758660731C71924100 @default.
• W2758660731 hasConceptScore W2758660731C84606932 @default.
• W2758660731 hasConceptScore W2758660731C98717036 @default.
• W2758660731 hasIssue "2" @default.
• W2758660731 hasLocation W27586607311 @default.
• W2758660731 hasOpenAccess W2758660731 @default.
• W2758660731 hasPrimaryLocation W27586607311 @default.
• W2758660731 hasRelatedWork W2028009983 @default.
• W2758660731 hasRelatedWork W2050936961 @default.
• W2758660731 hasRelatedWork W2375815296 @default.
• W2758660731 hasRelatedWork W2583320890 @default.
• W2758660731 hasRelatedWork W2584184160 @default.
• W2758660731 hasRelatedWork W2780055681 @default.
• W2758660731 hasRelatedWork W2953241133 @default.

• next